- Previous Close
16.20 - Open
16.32 - Bid --
- Ask --
- Day's Range
16.12 - 16.72 - 52 Week Range
5.25 - 19.00 - Volume
76,447 - Avg. Volume
78,009 - Market Cap (intraday)
475.259M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-0.88 - Earnings Date Dec 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.40
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
www.medincell.comRecent News: MEDCL.PA
View MorePerformance Overview: MEDCL.PA
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDCL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDCL.PA
View MoreValuation Measures
Market Cap
471.19M
Enterprise Value
510.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
50.26
Price/Book (mrq)
--
Enterprise Value/Revenue
55.75
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-209.61%
Return on Assets (ttm)
-39.49%
Return on Equity (ttm)
--
Revenue (ttm)
11.95M
Net Income Avi to Common (ttm)
-25.04M
Diluted EPS (ttm)
-0.88
Balance Sheet and Cash Flow
Total Cash (mrq)
19.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.6M